Vasin Lee / Shutterstock.com
Proactively managing patent portfolios is an investment that pays for itself in reduced patent costs. Bruno Reynolds, who works at the consultancy arm of Isis Innovation, the technology transfer company of the University of Oxford, explains more.
According to patent information company IFI Claims, 66% of what it said were the most prolific patenting companies also feature in the Financial Times’s top 500—compelling evidence that research and development (R&D) today creates tomorrow’s successes.
But which R&D outputs will be valuable? Which patents should companies and universities invest in?
Initial patent filings are cheap, making it easy to justify a cover-all-bases approach of patenting a high proportion of R&D outputs.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Bruno Reynolds; Oxford Gene Technology; Isis Enterprise; R&D; IP portfolio; University of Oxford